4Temple WJ, Saettler EB. Locally recurrent rectal cancer : role of composite resection of extensive pelvic tumors with strategies for minimizing risk of recurrence. J Surg Oneol, 2000,73 ( 1 ) :47 - 58.
5Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol, 2004, 22 (15) :3113 -3119.
6Tsuda G, Hasbiguchi Y, Nishimura S, et al. Phase I-II study of irinotecan ( CPT-II ) plus nedaplatin ( 254-S ) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer. Br J Cancer, 2004, 91 (6) : 1032 - 1037.
8Nag S, Ellis R J, Merrick GS, et al. American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys, 2002,54(2) :462 -470.
6Ankean MK, Decarvalho VS, Harangozo AM. et al. Implications of radioactive seed migration to the lungs after prostate brachytherapy [J]. Urology, 2002, 59(6):555-559.
7Popescu CC, Wine I, Soward K, et al. Dosimetric characteristics of the Pharma Seed model BT-125-I source [J]. Med Phys,2000,27 (9); 2174-2181.
8Reniers B, Verhaegen F, Vynckier S. The radial dose function of low energy brachytherapy seeds in different solid phantoms: comparison between calculations with the EGSnrc and MCNP4C Monte Cerlo codes and measurements [J]. Phys Med Biol, 2004,49(8):1569-1582.
9Pantelis E, Lymperopoulon G, Papagiaunis P, et al. Polycer gel dosime-try close to an ^125I interstitial brachytherapy seed [J]. Plays Med Biol, 2001,21:4371-4384.
10Nag S, Ellis R J, Marrick GS, et al. American Brachytherapy Society recommendations for reporting morbidity aider prostate brachytherapy [J]. Int J Radiat Oncol Biol Phys, 2002,54:4622470.
